Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | CheckMate 9ER: glycoproteomic biomarkers for nivolumab and cabozantinib in aRCC

Camillo Porta • 14 Sep 2024
ESMO 2024
Genitourinary Cancer Kidney Cancer Antibodies Cabozantinib Checkpoint Inhibitors Nivolumab Sunitinib
CheckMate 9ER

Camillo Porta, MD, A. Moro University of Bari, Bari, Italy, explores the CheckMate 9ER trial (NCT03141177), which investigated protein glycosylation as predictive biomarkers for nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC). Glycopeptides were identified as associated with progression-free survival and overall survival. Higher levels of protein fucosylation and sialylation correlated with poorer outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Camillo Porta

Optimizing outcomes in patients with renal cancer and bone metastases
0:55
Optimizing outcomes in patients with renal cancer and bone metastases
Camillo Porta • 20 Oct 2025
How can clinicians treat oligoprogression in renal cell carcinoma?
0:46
How can clinicians treat oligoprogression in renal cell carcinoma?
Camillo Porta • 20 Oct 2025
Multidisciplinary management of bone metastases in renal cancer
1:04
Multidisciplinary management of bone metastases in renal cancer
Camillo Porta • 20 Oct 2025
CLEAR: final analysis of lenvatinib & pembrolizumab in aRCC with bone metastases
0:44
CLEAR: final analysis of lenvatinib & pembrolizumab in aRCC with bone metastases
Camillo Porta • 20 Oct 2025

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals